CIK 0001607678 · Large accelerated filer
Viking Therapeutics, Inc.
Sign in to watch- Ticker
- VKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 461073877
- Phone
- 858-704-4660
- Business address
- 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −6,050 | $79.78 | $483K | 158,539 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −7,967 | $80.65 | $643K | 150,572 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −1,206 | $81.44 | $98K | 149,366 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,750 | 0 | ||
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,251 | 0 | ||
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −26,000 | 0 | ||
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −51,000 | 153,000 | ||
| 2024-10-25 | Rouan Sarah Kathryn Director | Option exercise 10b5-1 | +11,000 | $4.88 | $54K | 11,000 |
| 2024-10-25 | Rouan Sarah Kathryn Director | Sale 10b5-1 | −11,000 | $80.89 | $890K | 0 |
| 2024-10-25 | Rouan Sarah Kathryn Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,000 | 11,000 | ||
| 2024-10-25 | SINGLETON J MATTHEW Director | Option exercise 10b5-1 | +16,000 | $4.48 | $72K | 25,500 |
| 2024-10-25 | SINGLETON J MATTHEW Director | Sale 10b5-1 | −16,000 | $79.50 | $1.3M | 9,500 |
| 2024-10-25 | SINGLETON J MATTHEW Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,000 | 0 | ||
| 2024-09-20 | SINGLETON J MATTHEW Director | Option exercise 10b5-1 | +10,300 | $1.19 | $12K | 19,800 |
| 2024-09-20 | SINGLETON J MATTHEW Director | Sale 10b5-1 | −10,300 | $69.50 | $716K | 9,500 |
| 2024-09-20 | SINGLETON J MATTHEW Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,300 | 0 | ||
| 2024-09-20 | Lian Brian President & CEO | Option exercise 10b5-1 | +166,130 | $7.77 | $1.3M | 2,521,057 |
| 2024-09-20 | Lian Brian President & CEO | Sale 10b5-1 | −96,056 | $70.43 | $6.8M | 2,425,001 |
| 2024-09-20 | Lian Brian President & CEO | Sale 10b5-1 | −119,874 | $71.15 | $8.5M | 2,305,127 |
| 2024-09-20 | Lian Brian President & CEO | Sale 10b5-1 | −200 | $71.99 | $14K | 2,304,927 |
Page 6 of 27 · 528 trades